Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Terminated 1Recruiting 1Completed 1

Sponsor Class

OTHER 1NIH 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 13Genitourinary 9Gastrointestinal 9Head & Neck 7Dermatologic 5Thoracic 3Breast 3Other solid neoplasm 1Lymphoid 1

Conditions

Carcinoma, Non-Small-Cell Lung 27Ovarian Neoplasms 14Lung Neoplasms 12Melanoma 11Colorectal Neoplasms 9Breast Neoplasms 9Stomach Neoplasms 7Pancreatic Neoplasms 7Triple Negative Breast Neoplasms 6Neoplasms 6Neoplasm Metastasis 6Mesothelioma 6Carcinoma, Merkel Cell 5Small Cell Lung Carcinoma 4Multiple Myeloma 4Mesothelioma, Malignant 4Head and Neck Neoplasms 4Esophageal Neoplasms 4Carcinoma, Transitional Cell 4Carcinoma, Renal Cell 4Carcinoma, Hepatocellular 4Uterine Cervical Neoplasms 3Urogenital Neoplasms 3Urinary Bladder Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Recurrence 3Liver Neoplasms 3Cholangiocarcinoma 3Carcinoma, Squamous Cell 3Thymoma 2

Interventions

pembrolizumab 30Nivolumab 12Carboplatin 6atezolizumab 5Trastuzumab 5aldesleukin 4Specimen Handling 4Paclitaxel 4Magnetic Resonance Spectroscopy 4Ipilimumab 4Docetaxel 4Cyclophosphamide 4Cisplatin 4Bevacizumab 4spartalizumab 3fludarabine 3durvalumab 3Polymerase Chain Reaction 3Irinotecan 3Interleukin-2 3Gene Expression Profiling 3Blood Specimen Collection 3Biopsy 3zimberelimab 2tisotumab vedotin 2tislelizumab 2sargramostim 2osimertinib 2enzalutamide 2cemiplimab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Uterine Cervical Neoplasms × fludarabine × Thoracic × Clear all
NCT06630611 2025-01-28

PragmaTIL

Vall d'Hebron Institute of Oncology

Phase 2 Recruiting
40 enrolled
DermatologicGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Melanoma

NCT03841110 2023-05-01

FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors

Fate Therapeutics

Phase 1 Completed
37 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidThoracic

Breast Neoplasms, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Lymphoma, Melanoma, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

NCT01583686 2019-10-14

CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer

National Institutes of Health Clinical Center (CC)

Phase 1/2 Terminated
15 enrolled 14 charts
GastrointestinalGynecologicOther solid neoplasmThoracic

Uterine Cervical Neoplasms, Lung Neoplasms, Mesothelioma, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡